Merck, Sun Pharma Establish Generics JV

Merck & Co. and Sun Pharmaceutical Industries have created a joint venture to develop, manufacture and commercialize new combinations and formulations of branded generics in emerging markets. The partnership combines Sun Pharma’s product development expertise using Sun Pharma Advanced Research Company (SPARC) platform technologies, and manufacturing network, with Merck’s clinical development and registration expertise, and geographic commercial footprint. Financial details were not disclosed.

“Merck’s Emerging Markets strategy is driven by our overarching focus on applying innovation across our business from introducing novel compounds to broadening our focus on innovative branded generics,” said Kevin Ali, president, Emerging Markets, Merck/MSD. “By combining forces with Sun Pharma, we are complementing our innovative product portfolio with a solid foundation for addressing the diverse needs of patients, physicians and governments across the Emerging Markets.”

“This joint venture reinforces our strategy of partnering to launch products using our highly innovative delivery technologies around the world,” said Dilip S. Shanghvi, chairman and managing director, Sun Pharma. “Merck has an unrivalled reputation as a world leading, innovative, research-driven pharmaceutical company. We’re proud to be associated with them and look forward to working together.”